Abstract
Salivary gland carcinomas are a heterogeneous group of tumors that comprise about 5–10% of all oropharyngeal cancers. Tumor classification and stage have a significant impact on patient survival. Primary treatment of salivary gland carcinomas is surgical resection in combination with postoperative radiotherapy and/or chemotherapies when required. Molecular abnormalities as potential therapeutic targets differ between certain tumor types.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ho K, et al. An overview of the rare parotid gland cancer. Head Neck Oncol. 2011;3:40.
Prenen H, Kimpe M, Nuyts S. Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets. Curr Opin Oncol. 2008;20(3):270–4.
Adelstein DJ, et al. Biology and management of salivary gland cancers. Semin Radiat Oncol. 2012;22(3):245–53.
Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 1986;8(3):177–84.
Zhu S, Schuerch C, Hunt J. Review and updates of immunohistochemistry in selected salivary gland and head and neck tumors. Arch Pathol Lab Med. 2015;139(1):55–66.
Mancuso TF, Brennan MJ. Epidemiological considerations of cancer of the gallbladder, bile ducts and salivary glands in the rubber industry. J Occup Med. 1970;12(9):333–41.
Muscat JE, Wynder EL. A case/control study of risk factors for major salivary gland cancer. Otolaryngol Head Neck Surg. 1998;118(2):195–8.
Whatley WS, Thompson JW, Rao B. Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg. 2006;134(3):385–8.
Douglas JG, et al. Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys. 2000;46(3):551–7.
Huber PE, et al. Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol. 2001;59(2):161–7.
Chen N, Debnath J. Autophagy and tumorigenesis. FEBS Lett. 2010;584(7):1427–35.
Jee KJ, et al. Genomic profiles and CRTC1-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma. Mod Pathol. 2013;26(2):213–22.
Pusztaszeri MP, Faquin WC. Update in salivary gland cytopathology: recent molecular advances and diagnostic applications. Semin Diagn Pathol. 2015;32(4):264–74.
Agulnik M, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(25):3978–84.
Xia R, et al. High expression of H3K9me3 is a strong predictor of poor survival in patients with salivary adenoid cystic carcinoma. Arch Pathol Lab Med. 2013;137(12):1761–9.
Xia R-H, et al. Low expression of endothelin receptor B (EDNRB) is related to H3K9me3 binding with the EDNRB promoter region and is associated with the clinical T tumor stage in salivary adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(2):258–68.
Persson M, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009;106(44):18740–4.
West RB, et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol. 2011;35(1):92–9.
Hotte SJ, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(3):585–90.
Pfeffer MR, et al. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007;43(1):33–6.
Argiris A, et al. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011;117(15):3374–82.
Barnes EL, Eveson JW, Reichart P, Si-dransky D. Tumors of the salivary glands: introduction. WHO classification of tumours: pathology & genetics. Head and neck tumours. Lyon: IARCPress; 2005. p. 221–2.
Miettinen M, Wang Z-F, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33(9):1401–8.
Mitelman F, Johansson B, Mertens F. Database of chromosome aberrations and gene fusions in cancer. 2014. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
Stenman G, Persson F, Andersson MK. Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol. 2014;50(8):683–90.
Diegel CR, et al. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res. 2010;70(22):9143–52.
Murrah VA, Batsakis JG. Salivary duct carcinoma. Ann Otol Rhinol Laryngol. 1994;103(3):244–7.
Williams MD, et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol. 2007;31(11):1645–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Wolf, A. (2017). Parotid Cancer. In: Haybaeck, J. (eds) Mechanisms of Molecular Carcinogenesis – Volume 1. Springer, Cham. https://doi.org/10.1007/978-3-319-53659-0_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-53659-0_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-53657-6
Online ISBN: 978-3-319-53659-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)